Last updated: 11/07/2018 18:20:48
A randomized, double-blind, placebo-controlled, parallel group evaluation of oral naratriptan 1mg and 2.5mg twice daily as prophylactic treatment for menstrually-associated migraine.
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A randomized, double-blind, placebo-controlled, parallel group evaluation of oral naratriptan 1mg and 2.5mg twice daily as prophylactic treatment for menstrually-associated migraine.
Trial description: A randomized, double-blind, placebo-controlled, parallel group evaluation of oral naratriptan 1mg and 2.5mg twice daily as prophylactic treatment for menstrually-associated migraine.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Abstract: Menstrual migraine prophylaxis: emerging role of naratriptan. Mannix, L Ten Years of Improving the Lives of Migraine Patients Around the World -- GlaxoWellcome; Sponsored Satellite Symposium to Headache World 2000: Incorporating the 13th Migraine Trust International Symposium, Special Millennial International Headache Congres 9/3/2000 London, UK
Abstract: Naratriptan as prophylaxis for menstrually associated migraine: a randomized, double-blind, placebo-controlled study. L. C. Newmanl, L. K. Mannix S. H. Landy S. D. Silberstein R. B. Lipton G. P. Putnam M. M. JÃ bsis A. S. Batenhorst S. V. O'Quinn6 5th Congress of the European Federation of Neurological Societies (EFNS) 10/14/2000 Copenhagen, Denmark
Abstract: Naratriptan as prophylaxis for menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Newman, L C, Mannix, L K, Landy, S H, Silberstein, S D, Lipton, R B, Putnam, G P, Jobsis, M M, Batenhorst, A S, and O'Quinn, S V Headache World 2000: Incorporating the 13th Migraine Trust International Symposium, Special Millennial International Headache Congress of the International Headache Society, 5th European Headache Federation Conference and 1st Global Convention of the Worl 9/3/2000 London, UK
Abstract: Naratriptan as prophylaxis for menstrually-associated migraine: a randomized, double-blind, placebo-controlled study. Newman, L C MD, Mannix, L K MD, Landy, S H MD, Silberstein, S D MD, Putnam, G P MD, Jobsis, M M MD, Batenhorst, A S MD, and O'Quinn, S V MD American Academy of Neurology 52nd Annual Meeting 4/29/2000 San Diego, CA
Abstract: Naratriptan as prophylaxis for menstrually-associated migraine: a randomized, double-blind, placebo-controlled study. Newman, L C, Mannix, L K, Silberstein, S D, Lipton, R B, Putnam, G P, and O'Quinn, S V American Headache Society 42nd Annual Scientific Meeting 6/23/2000 (Location not available)
Abstract: Naratriptan as short-term prophylaxis of menstrually-associated migraine: a randomized, double-blind, placebo-controlled study. Newman, l, Mannix, L K, Landy, S, Silberstein, S, Lipton, R B, Pait Putnam, D G, Watson, C, Jobsis, M, Batenhorst, A, and O'Quinn, S 10th International Headache Research Seminar: The Triptans: Novel Drugs for Migraine 12/1/2000 Copenhagen, Denmark
Newman L, Mannix LK, Landy S, Silberstein S, Lipton RB, Putnam DG, Watson C, Jobsis M, Batenhorst A, O'Quinn S. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache. 2001 Mar;41(3):248-56.
Medical condition
Migraine Disorders
Product
naratriptan
Collaborators
Not applicable
Study date(s)
April 1998 to May 1999
Type
Not applicable
Phase
4
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1999-25-05
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website